Multiple myeloma - lenalidomide: final appraisal determination

After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on lenalidomide for multiple myeloma in people who have received at least one prior therapy and submitted it to the Institute.

The FAD has been sent to the formal consultees for this appraisal who, for this appraisal, have 20 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.

Please note that the appeal period for this appraisal will close at 5pm on 15 May 2009.

This page was last updated: 30 March 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.